BPC November 12 update

Urovant UROV buyout - shares up 90% AH; ​Cassava SAVA offering -18% AH

Price and Volume Movers

Urovant Sciences (NASDAQ:UROV) shares have spiked after hours, currently trading up 90% to $15.75 on news that Sumitovant Biopharma will acquire the outstanding shares of Urovant not already owned by Sumitovant at a price of $16.25 per share in cash. Sumitovant currently owns 72% of Urovant common stock.

Akers Biosciences, Inc. (NASDAQ:AKER) shares closed up 29% to $2.22 on news of a reverse merger with MyMD Pharmaceuticals, Inc. Upon closing the transaction, the combined company is expected to be renamed MyMD Pharmaceuticals, Inc. and remain listed on Nasdaq under the new ticker symbol "MYMD." Current Akers' shareholders will own approximately 20% of the combined company.

Cassava Sciences, Inc. (NASDAQ:SAVA) announced that it is commencing an underwritten public offering of shares of its common stock. Shares are trading down 18% after hours to $9.15.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) shares are trading up 32% after hours to $2.96 following the release of updated data from its ongoing Phase 2b NAV3-31 trial in patients with rheumatoid arthritis.

Histogen Inc. (NASDAQ:HSTO) announced a registered direct offering of 2,522,784 shares of its common stock, at a purchase price of $1.78375 per share and in a concurrent private placement, unregistered warrants to purchase up to a further 1,892,088 shares, for gross proceeds of $4.5m. Shares closed down 13% to $1.47.

-

Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Five Prime Therapeutics, Inc. (FPRX): $22.43; +25%.

Cidara Therapeutics, Inc. (CDTX): $2.52; +24%.

Kazia Therapeutics Limited (KZIA): $7.73; +17%.

Vaxart, Inc. (VXRT): $5.31; +15%.

Atara Biotherapeutics, Inc. (ATRA): $18.12; +15%.

DECLINERS:

Liquidia Technologies, Inc. (LQDA): $4.19; -14%.

IMV Inc. (IMV): $3.49; -13%.

Bellerophon Therapeutics, Inc. (BLPH): $7.87; -13%.

Oncternal Therapeutics, Inc. (ONCT): $4.66; -13%.

Aptevo Therapeutics Inc. (APVO): $42.30; -13%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AMTI – Applied Molecular Transport Inc.
AMT-101 (FILLMORE)
Pouchitis

Phase 2 Phase 2 trial planned for 2020.
$1.1 billion

BTAI – BioXcel Therapeutics Inc.
BXCL501 (TRANQUILITY)
Agitation associated with dementia

Phase 1b Phase 1b data due 4Q 2020.
$1.1 billion

CAPR – Capricor Therapeutics Inc.
CAP-1002 (INSPIRE)
COVID-19

Phase 2 Phase 2 trial initiation of dosing announced November 24, 2020 with data due 2Q 2021.
$85.9 million

CCCC – C4 Therapeutics Inc.
CFT8634
Synovial sarcoma

Phase 1/2 Phase 1/2 trial to be initiated 2H 2021.
$1.5 billion

CRTX – Cortexyme Inc.
COR388 - GAIN
Alzheimer’s disease

Phase 2/3 Phase 2/3 interim analysis to occur December 2020. Final data due 4Q 2021.
$1.4 billion

DFFN – Diffusion Pharmaceuticals Inc.
Trans sodium crocetinate (TSC) - 100-303 COVID
COVID-19

Phase 1b Phase 1a/b data due 1Q 2021.
$48.8 million

ETON – Eton Pharmaceuticals Inc.
Ephedrine Injection (ET-203)
Injectable hospital product

PDUFA PDUFA date June 18, 2021.
$192.3 million

HALO – Halozyme Therapeutics Inc.
Daratumumab in combination with pomalidomide and dexamethasone
Multiple myeloma

Phase 3 Phase 3 data to be presented at ASH December 6, 2020. sBLA filing announced November 12, 2020.
$5.3 billion

IMVT – Immunovant Inc.
IMVT-1401 (ASCEND-WAIHA)
Warm autoimmune hemolytic anemia

Phase 2 Phase 2a data from high-dose cohort due 1Q 2021.
$4 billion

OVID – Ovid Therapeutics Inc.
OV101 - NEPTUNE
Adolescents with Angelman syndrome

Phase 3 Phase 3 data due 4Q 2020.
$433.9 million

PHAS – PhaseBio Pharmaceuticals Inc.
PB1046
Pulmonary arterial hypertension (PAH)

Phase 2b Phase 2b data due 2H 2021.
$111.6 million

SLGL – Sol-Gel Technologies Ltd.
Twyneo
Acne

NDA Filing NDA filing has been submitted.
$207 million

SNGX – Soligenix Inc.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer

Phase 3 Phase 3 top-line data due 4Q 2020.
$67.8 million

SWTX – SpringWorks Therapeutics Inc.
Mirdametinib
Neurofibromas

Phase 2b Phase 2b update 4Q 2020 / 1Q 2021.
$3.2 billion

TGTX – TG Therapeutics Inc.
Repotrectinib (TPX-0005) - TRIDENT-2
KRAS mutant NSCLC

Phase 2 Phase 2 trial to be initiated mid-2021.
$3.9 billion